Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.
Approval Alert | Pembrolizumab/Chemotherapy in Advanced/Recurrent Endometrial Carcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
SABCS 2025: The Top 5 Takeaways for Breast Cancer Research
2
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
3
FDA Grants Fast Track Designation to GPC3x4-1BB Bispecific Antibody in HCC
4
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
5